PAUL CARTER: Open Payments
NPI 1639205792 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,537 in 69 payments from 22 companies in 2025. Trend: 2023 $2,291 · 2024 $1,911 · 2025 $1,537
Food & beverage: $1,537
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $179 |
| ABBVIE INC. | 12 | $177 |
| Novo Nordisk Inc | 7 | $147 |
| Exact Sciences Corporation | 5 | $128 |
| Lilly USA, LLC | 6 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $120 |
| GlaxoSmithKline, LLC. | 3 | $84 |
| Vanda Pharmaceuticals Inc. | 2 | $70 |
| Astellas Pharma US Inc | 2 | $68 |
| PFIZER INC. | 3 | $56 |
Products named: Cologuard Collection Kit, MOUNJARO, CAPLYTA, AIRSUPRA, VRAYLAR, TRELEGY ELLIPTA, REXULTI, FANAPT.
Industry payments across PA — which companies pay providers there.
